


Emily HM Wong¹, David Ficenc², David Merberg¹, Yulia Skovpen³, Alena Fedarovich³, Tyler Kolisnik³, Oksana Tyurina³, Christine Loreth³, Mahyar Sabripour¹, Bin Li¹, Yan Ge¹, Tania Khasanova³, Julie Bryant³, Sandor Szalma¹

¹Data Science Institute and ²Information Technology, Takeda Pharmaceuticals, USA; ³ Rancho Biosciences, USA

Introduction

- UK Biobank collects vast amounts of phenotype data and provides a valuable resource for studying the complex relationships between the human genome and phenome.
- As part of the UKB-Pharma consortium, we are building a pipeline to process available UK Biobank data. To facilitate downstream analyses, we and Rancho Biosciences first extensively curated phenotype data from all UK Biobank participants.



Goal

Curate the UK Biobank data by aggregating and integrating the disparate datasets into a single comprehensive resource

- Flat files (PheWAS ready)
- transSMART ready files

Curation Process: Overview

Beginning of 2018: **502,616 subjects**
3,390 data fields



- Data inspection
- UKB coding files update
- Creation of decoded version
- Preparation of supporting files for PheWAS
 - e.g. code reassignment file, field ID–coding file mapping, summary statistics file, etc.

- Harmonization of inconsistent data in multiple instances
- ~100 harmonization rules have been proposed and implemented

- RXNORM
- SNOMED
- ICD10
- MeSH

- Data preparation for PheWAS analysis
- Data conversion into a human-readable format to assist the translational biomedical research
- Upload of UKB phenotype data onto transSMART

UK Biobank in transSMART

- The transSMART platform is a knowledge management architecture for translational medicine.
- It allows for mining and searching multi-model data, including clinical and biomarker data.

Folder: UK BioBank Curated Dataset 2018

The loaded in transSMART UK BioBank dataset contains information for 10,000 subjects. The full version of the dataset is attached in Browse transSMART page. The dataset contains data collected by UK Biobank in April 2018. The full dataset is divided into two major parts: "High priority data" and "Medium and low priority data". The separation of data is based on Takeda "Data_Dictionary_Showcase_prioritized_list.xlsx" attached below. The transSMART study tree fully corresponds to UK BioBank Categories: <http://biobank.ctsu.ox.ac.uk/crystal/cats.cgi>.

Property	File Type	Value
Provider name	Report	UK BioBank https://www.ukbiobank.ac.uk/
Provider email	ETL files	access@ukbiobank.ac.uk
	Raw data	

File Name	Size	Created on	Updated on	
data_codes_v3.7z	663125	2018-10-04	2018-10-04	Add to export Delete
Data_Dictionary_Showcase_prioritized_list.xlsx	426106	2018-10-01	2018-10-01	Add to export Delete
Takeda_UKB_curation_summary_v1_transmart.pdf	535538	2018-10-05	2018-10-05	Add to export Delete
transmart_summary_file_UKB_high_priority.xlsx	390685	2018-10-05	2018-10-05	Add to export Delete
transmart_summary_file_UKB_medium_and_low_priority.xlsx	709608	2018-10-05	2018-10-05	Add to export Delete
UKB_high_priority_data_tm.7z	356487830	2018-10-04	2018-10-04	Add to export Delete
UKB_medium_and_low_priority_data_tm.7z	645542439	2018-10-05	2018-10-05	Add to export Delete

Identifying drug targets and pleiotropy

- Genomics data and the curated phenotype data were loaded onto a Spark and Hail framework on Amazon Databricks.
- This allows us to efficiently perform PHEWAS and GWAS to identify drug targets and pleiotropy in three major therapeutic areas – gastroenterology, neuroscience, and oncology.